The state-of-the-art, 35,000-square-foot facility represents a major milestone in Novartis’ $23 billion U.S. investment strategy and underscores the Orlando region’s growing reputation as a hub for advanced manufacturing and life sciences innovation.
Photo Courtesy Novartis
Novartis, a leading global innovative medicines company, announced plans to build its fourth U.S. radioligand therapy (RLT) manufacturing facility in Winter Park, Florida, marking a significant investment in the Orlando region’s life sciences sector.
The 35,000-square-foot, built-for-purpose facility will come online by 2029 and represents a key milestone in Novartis’ $23 billion U.S. investment strategy announced in April 2025. The facility is expected to come online by 2029 and will create 50 high-quality jobs in the region over the next three years with an average salary of $90,000.
“Building this new facility in Florida marks an important step in fulfilling the promise of RLT for patients.”
Vas Narasimhan, CEO of Novartis
“Radioligand therapy has fundamentally changed how we approach certain cancers, and our growing US manufacturing network ensures we can continue to deliver these critical medicines with speed and reliability to patients who need them,” said Vas Narasimhan, CEO of Novartis.
RLT manufacturing requires specialized talent, a key factor in determining the location for each new facility. Florida has steadily invested in higher education for life sciences and technology, helping to build the next generation of leaders critical to driving forward advanced manufacturing for platforms like RLT. With a growing skilled workforce and a regulatory and policy environment that values pharmaceutical innovation, Florida is well positioned to become a leader in pharmaceutical manufacturing.
“Thanks to deliberate, focused, intensified investments and world class health innovation partnerships, we have led Florida to become a national and world-recognized leader for breakthroughs in cancer treatment, neurological innovations, and more.”
Florida Secretary of Commerce J. Alex Kelly
“Novartis’ investment in manufacturing cancer medicines here in Florida—where we’re already #2 nationally in both manufacturing for medicine and medical device technology—is an incredible opportunity to welcome world class innovators to our incredibly collaborative and impactful life sciences community,” said Florida Secretary of Commerce J. Alex Kelly.
Novartis will be investing over $75 million into its new expansion, strengthening its specialized supply chain and ensuring timely delivery of these life-saving therapies to patients across the Southeast.
“Novartis’ decision to expand in Orlando underscores our region’s strength and value as a hub for advanced manufacturing and life sciences innovation.”
Tim Giuliani, President and CEO of the Orlando Economic Partnership
“Bringing together collaborative city, county, and state partners ensures companies like Novartis have the resources and support they need to thrive in our vibrant economic ecosystem,” said Tim Giuliani, President and CEO of the Orlando Economic Partnership. “The global healthcare leader’s mission and values align with the vision for our region as a global creative capital and we are proud to welcome them to our dynamic community.”
This expansion was made possible through the combined efforts of the Orlando Economic Partnership, Florida Department of Commerce, Orange County, Duke Energy, and local partners, demonstrating the region’s commitment to fostering innovation and economic growth.
“Thanks to a strong collaborative relationship with the Orlando Economic Partnership, Central Florida will soon welcome Novartis, an innovative pharmaceutical manufacturer, bringing 50 new jobs to the region.”
Melissa Seixas, President, Duke Energy Florida
“Through collaboration on site selection, power planning and customized energy solutions, our teams were able to help meet the company’s operational and timeline needs as they invest $75 million in the region – strengthening the Central Florida economy,” said Melissa Seixas, President, Duke Energy Florida.
Novartis and radioligand therapy (RLT)
Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells anywhere in the body.
As the sole company with two FDA-approved RLT treatments and an extensive RLT pipeline across several tumors and targets, Novartis has global expertise in this cutting-edge technology platform that is transforming cancer care. That knowledge has fueled advancements in manufacturing techniques to build capacity and consistently deliver with confidence for patients and healthcare providers.
Novartis is actively investigating the application of RLTs across cancer types and settings, with one of the deepest and most advanced pipelines in the industry, with trials in prostate cancer, breast, colon, lung, brain, pancreatic and other cancers. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites around the world.
Radioligand therapy is a precision oncology treatment that pairs a tumor-targeting molecule with a therapeutic radioisotope, delivering radiation directly to cancer cells while minimizing harm to healthy tissue. Each dose is individually prepared and highly time-sensitive, making proximity to treatment centers and transportation hubs critical.
Over the next 5 years, Novartis will solidify its robust US RLT manufacturing network. The new Florida site is the fourth of five existing or planned facilities. The company is currently investing in expansions of its RLT facilities in Indiana and New Jersey. In November, Novartis announced completion of a new RLT facility in California, and it plans to build a fifth location in the US.
About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.